Get the Stockscreener App
0.9298
1.09%
-0.0102
Biofrontera Inc stock is traded at $0.9298, with a volume of 3,109.
It is down -1.09% in the last 24 hours and down -21.20% over the past month.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
See More
Previous Close:
$0.94
Open:
$0.93
24h Volume:
3,109
Relative Volume:
0.01
Market Cap:
$8.34M
Revenue:
$34.07M
Net Income/Loss:
$-20.13M
P/E Ratio:
-0.072
EPS:
-12.92
Net Cash Flow:
$-24.90M
1W Performance:
+1.07%
1M Performance:
-21.20%
6M Performance:
-27.92%
1Y Performance:
-46.87%
1-Day Range:
$0.9248
$0.9396
1-Week Range:
$0.859
$0.9682
52-Week Range:
$0.6513
$2.4302
Biofrontera Inc Stock (BFRI) Company Profile
Name
Biofrontera Inc
Sector
Phone
781-245-1325
Address
120 PRESIDENTIAL WAY,, WOBURN
Compare BFRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BFRI
Biofrontera Inc
|
0.9396 | 8.34M | 34.07M | -20.13M | -24.90M | -12.92 |
|
ZTS
Zoetis Inc
|
159.50 | 71.40B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.01 | 47.36B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.17 | 46.03B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.27 | 18.86B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.27 | 13.96B | 612.78M | -86.37M | -62.91M | -0.87 |
Biofrontera Inc Stock (BFRI) Latest News
Biofrontera (BFRI) to Release Earnings on Friday - Defense World
BIOFRONTERA Earnings Preview: Recent $BFRI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - GlobeNewswire
Dermatology Leader Biofrontera Sets Q4 Earnings Date: Key Growth Updates Expected - StockTitan
Biofrontera (BFRI) Projected to Post Earnings on Thursday - Defense World
Biofrontera Inc. (NASDAQ:BFRI) Short Interest Down 25.0% in February - Defense World
Investors Aren't Entirely Convinced By Biofrontera Inc.'s (NASDAQ:BFRI) Revenues - Simply Wall St
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Yahoo Finance
Biofrontera (NASDAQ:BFRI) Trading Down 3.5% – What’s Next? - Defense World
Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World
Biofrontera (NASDAQ:BFRI) vs. Sage Therapeutics (NASDAQ:SAGE) Critical Contrast - Defense World
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts - ACCESS Newswire
Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals - ACCESS Newswire
Biofrontera Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on March 15, 2024 - ACCESS Newswire
Biofrontera Inc. Announces Preliminary Third Quarter Revenues - ACCESS Newswire
Biofrontera says last patient completed one-year follow-up in Ameluz-PDT study - TipRanks
Biofrontera Inc. Announces Achievement of Key Milestone In - GlobeNewswire
Biofrontera's Ameluz-PDT Skin Cancer Treatment Hits All Phase 3 Endpoints with Strong Results - StockTitan
Photonics IP Update: December 2024 - Laser Focus World
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - The Manila Times
Biofrontera Hits Major Milestone: 100th RhodoLED® XL Lamp Installed as PDT Treatment Demand Surges - StockTitan
Opendoor Technologies Inc (OPEN-Q) QuotePress Release - The Globe and Mail
Financial Contrast: Biofrontera (NASDAQ:BFRI) versus Amicus Therapeutics (NASDAQ:FOLD) - Defense World
Why Stitch Fix Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga
Biofrontera Inc (BFRI:UR): Stock Price, Quote and News - BNN Bloomberg
Biofrontera to Present at Benchmark's Discovery Investor Conference in NYC - StockTitan
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Yahoo Finance
Biofrontera Inc. announced that it expects to receive $4.2 million in funding - Marketscreener.com
Biofrontera Closes a $4.2 Million Senior Secured Convertible Note - citybiz
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - GlobeNewswire
Biofrontera Secures $4.2M for Strategic Growth Initiatives - TipRanks
Biofrontera Secures $4.2M Financing Through Convertible Note Deal with Key Shareholders | BFRI Stock News - StockTitan
Biofrontera AG announced that it has received $4.2 million in funding - Marketscreener.com
Biofrontera Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Earnings call: Biofrontera reports modest revenue growth in Q3 2024 - Investing.com
Biofrontera Inc. (NASDAQ:BFRI) Q3 2024 Earnings Call Transcript - Insider Monkey
Biofrontera Inc. (BFRI) Quarterly 10-Q Report - Quartzy
ARMISTICE CAPITAL, LLC Acquires New Stake in Biofrontera Inc - GuruFocus.com
Biofrontera Inc. Reports Q3 2024 Earnings Growth - TipRanks
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - MSN
Biofrontera Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - GlobeNewswire
Biofrontera Reports Record Ameluz Volume, Phase 3 Study Shows 76% Clearance Rate | BFRI Stock News - StockTitan
Siga Technologies (SIGA) Sees Significant Stock Decline Amidst P - GuruFocus.com
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc. - GuruFocus.com
Ameluz photodynamic therapy yields positive results in first US phase 3 study for sBCC - Healio
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Yahoo Finance
Biofrontera reports breakthrough in skin cancer treatment By Investing.com - Investing.com Australia
Biofrontera stock climbs as drug-device succeeds in Phase III skin cancer trial - Yahoo Finance
Biofrontera Announces Promising Phase 3 Study Results - TipRanks
Biofrontera reports breakthrough in skin cancer treatment - Investing.com
Biofrontera Inc Stock (BFRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):